LL-37

Clinical Trials

Immune Support

A human antimicrobial peptide (cathelicidin) with broad-spectrum antimicrobial, anti-biofilm, and immunomodulatory properties.

Administration

Subcutaneous injection

Dosage Range

50-100 mcg daily

Mechanism of Action

LL-37 disrupts bacterial membranes, prevents biofilm formation, recruits immune cells to infection sites, and modulates inflammatory responses through TLR signaling pathways.

Clinical Benefits

Broad-spectrum antimicrobial activity

Breaks down bacterial biofilms

Modulates inflammation

Supports wound healing

Enhances innate immunity

Clinical Evidence

Extensive in vitro and animal studies demonstrating antimicrobial efficacy. Clinical trials ongoing for chronic wound healing and respiratory infections. Used in functional medicine for chronic infections.

Side Effects

Injection site pain

Temporary redness

Mild flu-like symptoms

Contraindications

Autoimmune conditions

Pregnancy

Immunosuppressive therapy

Related Peptides in Immune Support

Thymosin Alpha-1

A thymic peptide that modulates immune function, enhances T-cell activity, and supports the body's defense against infections and cancer.

Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice. Peptide therapy should only be administered under the supervision of a qualified healthcare provider. Always consult your physician before starting any new treatment protocol.